Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Form 8.3 - Abcam Plc

8 May 2018 11:57

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser: Marathon Asset Management LLP
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Abcam Plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

4 May 2018
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: Ordinary shares

Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled: 3,542,824 1.73
(2) Cash-settled derivatives:
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL: 3,542,824* 1.73

* Marathon Asset Management LLP does not have discretion regarding voting decisions in respect of 540,242 shares that are included in the total above.

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security Purchase/sale Number of securities Price per unit
Ordinary shares Purchase 653 12.7699

(b) Cash-settled derivative transactions

Class of relevant security Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type

e.g. American, European etc.

Expiry date Option money paid/ received per unit

(ii) Exercise

Class of relevant security Product description

e.g. call option

Exercising/ exercised against Number of securities Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing

e.g. subscription, conversion

Details Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO
Date of disclosure: 8 May 2018
Contact name: Mary Davidge
Telephone number: 020 7497 2211

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180508005857/en/

Copyright Business Wire 2018

Date   Source Headline
16th Sep 20198:02 amRNSDirector/PDMR Shareholding
12th Sep 20197:00 amRNSNotice of Capital Markets Event
11th Sep 201910:33 amRNSDirector/PDMR Shareholding
11th Sep 201910:11 amRNSReplacement: Director/PDMR Shareholding
11th Sep 20197:00 amRNSDirector/PDMR Shareholding
9th Sep 20197:00 amRNSFull year results for 12 months ended 30 June 2019
2nd Sep 20193:14 pmRNSTotal Voting Rights
1st Aug 201912:10 pmRNSTotal Voting Rights
22nd Jul 20197:01 amRNSDirectorate Change
22nd Jul 20197:00 amRNSFull Year Trading Update
16th Jul 20197:00 amRNSAcquisition of Cell Lines and Lysates Portfolio
1st Jul 20199:38 amRNSTotal Voting Rights
3rd Jun 201910:45 amRNSTotal Voting Rights
2nd May 201912:53 pmRNSTotal Voting Rights
1st May 20197:00 amRNSAppointment of Joint Broker
2nd Apr 20191:13 pmRNSTotal Voting Rights
29th Mar 20197:00 amRNSCompany Secretary Change
12th Mar 20197:00 amRNSHolding(s) in Company
8th Mar 20198:57 amRNSHolding(s) in Company
4th Mar 20197:00 amRNSInterim results for six months ended 31 Dec 2018
1st Mar 201910:29 amRNSTotal Voting Rights
25th Feb 20195:39 pmRNSChange of Registered Office
18th Feb 20191:01 pmRNSBlock listing Interim Review
5th Feb 201911:34 amRNSTotal Voting Rights
28th Jan 20197:00 amRNSAcquisition of Calico Biolabs
8th Jan 20197:00 amRNSHalf Year Trading Update
3rd Jan 20191:45 pmRNSTotal Voting Rights
3rd Jan 20197:00 amRNSAbcam to present at J.P. Morgan Conference
13th Dec 201810:06 amRNSDirectorate Change
6th Dec 20181:06 pmRNSDirector/PDMR Shareholding
3rd Dec 20184:02 pmRNSDirector/PDMR Shareholding
3rd Dec 201812:21 pmRNSTotal Voting Rights
12th Nov 20181:59 pmRNSDirector/PDMR Shareholding
8th Nov 20189:32 amRNSDirector/PDMR Shareholding
6th Nov 20185:47 pmRNSResult of AGM
2nd Nov 20188:51 amRNSTotal Voting Rights
1st Nov 20181:22 pmRNSHolding(s) in Company
29th Oct 20188:57 amRNSDirector/PDMR Shareholding
10th Oct 201810:46 amRNSHolding(s) in Company
9th Oct 20188:59 amRNSDirector/PDMR Shareholding
2nd Oct 201812:54 pmRNSHolding(s) in Company
2nd Oct 201812:51 pmRNSDirector/PDMR Shareholding
1st Oct 20185:41 pmRNSTotal Voting Rights
28th Sep 201810:11 amRNSDirector/PDMR Shareholding
24th Sep 20182:42 pmRNSHolding(s) in Company
21st Sep 201812:56 pmRNSAnnual Financial Report
14th Sep 20189:46 amRNSDirector/PDMR Shareholding
13th Sep 20181:34 pmRNSDirector/PDMR Shareholding
13th Sep 20181:33 pmRNSDirector/PDMR Shareholding
11th Sep 201810:30 amRNSDividend Payment Date

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.